Sphere Fluidics transforms into Sphere Bio amid expanding single-cell analysis market
Sphere Fluidics, a pioneer in droplet-based microfluidics technology, has announced its comprehensive rebranding to Sphere Bio. The name change, revealed on 25th February 2025, signifies the company’s strategic pivot and commercial growth trajectory as it continues to expand its footprint in the single-cell analysis market.
Strategic repositioning reflects broader capabilities
The rebranding initiative comes at a pivotal moment for the Cambridge-based firm, which has undergone significant operational scale-up over the past two years. Since its founding in 2010, the company has built an impressive portfolio of novel single-cell analysis products and R&D services, attracting over £40 million in investment and securing 135 international patents.
This strategic repositioning reflects Sphere Bio’s evolution beyond its engineering foundations to address complex industry challenges with comprehensive solutions. The company has established collaborative relationships with over 400 international customers, including partnerships with seven of the world’s top 10 pharmaceutical companies.
Dale Levitzke, CEO of Sphere Bio, highlighted the significance of the rebrand: “Relaunching as Sphere Bio sets the stage for a transformative 2025 – it better represents us as a provider of integrated life sciences tools and solutions, while maintaining a strong basis in engineering. The new name maintains our strong brand recognition, reflecting the growth of the Company and its forward-looking approach, paving the way for an exciting future for our team and stakeholders.”
Claire Cox, Director of Global Marketing at Sphere Bio
Technical capabilities driving market expansion
At the core of Sphere Bio’s offering is its proprietary picodroplet technology, which enables ultra-high throughput functional analysis of live cells. This technical foundation has positioned the company to support increasingly sophisticated workflows across multiple application domains, including biologics discovery, cell therapy development, and synthetic biology.
The company’s flagship product, the industry-leading Cyto-Mine platform, alongside the recently launched next-generation Cyto-Mine Chroma platform, provides researchers with sophisticated tools for single-cell analysis and isolation. These platforms represent significant technological advancements that can dramatically accelerate research timelines, reducing typical project durations from months to weeks.
This technical capability has particular relevance for researchers working in biologics discovery and cell therapy development, where identifying and isolating cells with specific functional characteristics remains a critical bottleneck. By providing tools that facilitate more efficient workflows, Sphere Bio directly addresses key rate-limiting steps in therapeutic development pipelines.
Market trends driving commercial strategy
The rebranding strategy reflects broader industry trends, as pharmaceutical and biotechnology companies increasingly seek integrated workflow solutions rather than individual components. This shift towards comprehensive platforms aligns with the growing complexity of biotherapeutic development and the need for more efficient research tools.
Claire Cox, Director of Global Marketing at Sphere Bio, explained the company’s customer-centric approach: “Our solutions work small, so our customers can think big in their research. We are committed to evolving alongside our customers and their workflow needs to provide the best solutions for ultra-high throughput functional analysis of live cells. As we look toward identifying and supporting new emerging application areas, this is more important than ever.”
She added: “By expanding our product portfolio and global market presence, we are able to provide researchers with the cutting-edge tools and solutions to accelerate scientific discovery.”
Future growth trajectory
The rebranding initiative positions Sphere Bio for continued expansion into new application areas. The company’s technical expertise in microfluidics and single-cell analysis creates opportunities to address emerging research needs across multiple sectors of the life sciences industry.
This strategic positioning is particularly relevant as cellular therapies continue to advance through clinical development and the biologics market expands beyond traditional monoclonal antibodies to include more complex modalities. These trends create growing demand for sophisticated analytical tools that can characterize and isolate cells based on their functional properties rather than simple surface markers.
With its established customer base and proven technology platforms, Sphere Bio appears well-positioned to capitalize on these market opportunities as it enters this new phase under its updated brand identity.
